Clinical trial
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
NCT02678572 · Delcath Systems Inc., Industry · Completed
Key facts
| NCT number | NCT02678572 |
|---|---|
| Title | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma |
| Official title | A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma |
| Acronym | FOCUS |
| Lead sponsor | Delcath Systems Inc., Industry |
| Collaborators | IQVIA Biotech Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma, Ocular |
| Intervention type | Combination Product |
| Interventions | Melphalan/HDS |
| Enrollment | 102 |
| Start date | Feb 1, 2016 |
| Primary completion | May 18, 2023 |
| Completion | Aug 15, 2023 |
| First posted | Feb 10, 2016 |
| Last update posted | Dec 21, 2023 |
| Countries | Austria, Belgium, France, Germany, Italy, Spain, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: